Veracyte Q2 Revenues Rise 23 Percent | GenomeWeb

This article has been updated to clarify Veracyte's copromotion arrangement with Sanofi Genzyme.

NEW YORK (GenomeWeb) – Veracyte announced after the close of the market Wednesday a 23 percent rise in its second quarter revenues as the company continued to experience increased demand for its Afirma gene expression classifier thyroid test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.